Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: The InterLymph non-Hodgkin lymphoma subtypes project

Journal of the National Cancer Institute - Monographs

Volumn , Issue 48, 2014, Pages 87-97

  Vajdic, Claire M ^a   Landgren, Ola ^b   McMaster, Mary L ^b   Slager, Susan L ^c   Brooks Wilson, Angela ^e,f   Smith, Alex ^g   Staines, Anthony ^h   Dogan, Ahmet ⁱ   Ansell, Stephen M ^d   Sampson, Joshua N ^b   Morton, Lindsay M ^b   Linet, Martha S ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d MAYO CLINIC   (United States)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f SIMON FRASER UNIVERSITY   (Canada)

^g UNIVERSITY OF YORK   (United Kingdom)

^h DUBLIN CITY UNIVERSITY   (Ireland)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AUSTRALIA; CASE CONTROL STUDY; COMORBIDITY; ETHNOLOGY; EUROPE; FEMALE; HUMAN; LIFESTYLE; MALE; META ANALYSIS; MIDDLE AGED; NORTH AMERICA; OCCUPATIONAL EXPOSURE; RISK FACTOR; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA; YOUNG ADULT; ARTICLE; BODY WEIGHT; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FIRST DEGREE RELATIVE; HAY FEVER; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HODGKIN DISEASE; LEUKEMIA; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OCCUPATIONAL HAZARD; PHYSICIAN; POPULATION BASED CASE CONTROL STUDY; SEROLOGY; SJOEGREN SYNDROME; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CASE-CONTROL STUDIES; COMORBIDITY; EUROPE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NORTH AMERICA; OCCUPATIONAL EXPOSURE; RISK FACTORS; WALDENSTROM MACROGLOBULINEMIA; YOUNG ADULT;

EID: 84906829288     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgu002     Document Type: Article

References (53)

1. Swerdlow SH, Campo E, Harris NL et al., eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC Press; 2008.
2. Berger F, Isaacson PG, Piris MA, Vardiman JW. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:132-134.
3. Iwanaga M, Chiang CJ, Soda M, et al. Incidence of lymphoplasmacytic lymphoma/ Waldenstrom's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. Int J Cancer. 2014;134(1):174-180.
4. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
5. Altieri A, Bermejo JL, Hemminki K. Familial aggregation of lymphoplasmacytic lymphoma with non-Hodgkin lymphoma and other neoplasms. Leukemia. 2005;19(12):2342-2343.
6. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
7. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood. 2008;112(8):3052-3056.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759-3764.
9. Landgren O, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114(4):791-795.
10. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010-2017.
11. Koshiol J, Gridley G, Engels EA, et al. Chronic immune stimulation and subsequent Waldenstrom macroglobulinemia. Arch Intern Med. 2008;168(17):1903-1909.
12. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451-458.
13. Kristinsson SY, Koshiol J, Bjorkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102(8):557-567.
14. Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22):4464-4471.
15. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98(1):51-60.
16. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood. 1994;83(12):3647-3653.
17. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood. 1995;85(7):1913-1919.
18. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755-2763.
19. Liang XS, Caporaso N, McMaster ML, et al. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol. 2009;146(4):418-423.
20. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia. 1993;7(9):1363-1369.
21. Holly EA, Lele C, Bracci PM, et al. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol. 1999;150(4):375-389.
22. Hughes AM, Armstrong BK, Vajdic CM, et al. Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma. Int J Cancer. 2004;110(3):429-434.
23. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97(3):199-209.
24. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 2004;13(9):1415-1421.
25. Spinelli JJ, Ng CH, Weber JP, et al. Organochlorines and risk of non-Hodgkin lymphoma. Int J Cancer. 2007;121(12):2767-2775.
26. Chiu BC, Kolar C, Gapstur SM, et al. Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma: a population-based case-control study. Br J Haematol. 2005;128(5):610-615.
27. Morton LM, Holford TR, Leaderer B, et al. Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). Cancer Causes Control. 2003;14(7):687-694.
28. Besson H, Brennan P, Becker N, et al. Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: a European multicenter case-control study (Epilymph). Int J Cancer. 2006;119(4):901-908.
29. Monnereau A, Orsi L, Troussard X, et al. History of infections and vaccinations and risk of lymphoid neoplasms: does influenza immunization reduce the risk? Leukemia. 2007;21(9):2075-2079.
30. Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer. 2004;110(3):380-385.
31. Cerhan JR, Fredericksen ZS, Wang AH, et al. Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidemiol Genet. 2011;2(2):95-113.
32. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
33. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110(2):695-708.
34. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90-e98.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
36. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
37. Fisher SG, Fisher RI. The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol. 2006;18(5):417-424.
38. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):146-152.
39. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
40. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996;77(12):2604-2613.
41. Machida K, Cheng KT, Pavio N, et al. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol. 2005;79(13):8079-8089.
42. Fabris M, Quartuccio L, Sacco S, et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford). 2007;46(1):37-43.
43. Lake-Bakaar G, Jacobson I, Talal A. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol. 2012;170(2):231-237.
44. Vajdic CM, Falster MO, de Sanjose S, et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res. 2009;69(16):6482-6489.
45. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer. 2008;122(9):2062-2070.
46. Murphy F, Kroll ME, Pirie K, et al. Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 2013;108(11):2390-2398.
47. Bertrand KA, Giovannucci E, Zhang SM, et al. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res. 2013;6(8):864-873.
48. Meijer K, de Vries M, Al-Lahham S, et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One. 2011;6(3):e17154.
49. Kaminski DA, Randall TD. Adaptive immunity and adipose tissue biology. Trends Immunol. 2010;31(10):384-390.
50. Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Cancer Epidemiol Biomarkers Prev. 2005;14(4):925-933.
51. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol. 1998;83(1-2):148-156.
52. Karavitis J, Kovacs EJ. Macrophage phagocytosis: effects of environmental pollutants, alcohol, cigarette smoke, and other external factors. J Leukoc Biol. 2011;90(6):1065-1078.
53. International Labour Office. International Standard Classification of Occupations, Revised Edition 1968. Geneva, Switzerland: International Labour Office; 1969.